Table 4.
B cell subsets assessed by using “Bm1-Bm5” classification in Tbc patients and healthy subjects.
| B cell subset | Tbc patients (n=41) 95%Cl |
Healthy subjects (n=37) 95%Cl |
Significance | |
|---|---|---|---|---|
| Bm1, IgD+CD38- |
9.21 (5.58; 13.99) | 14.88 (9.91; 19.13) | p = 0.001 | |
| %(Cl95%) | 18.0 (9; 29) | 30.0 (18; 50) | p = 0.002 | |
| Bm2, IgD+CD38+ |
59.4 (49,23; 66,83) | 53.2 (47.06; 62.6) | p = 0.317 | |
| %(Cl95%) | 122 (64; 184) | 132 (86; 178) | p = 0.722 | |
| Bm2’ IgD+CD38++ |
11.78 (6.49; 16.21) | 4.41 (2.69; 6.45) | p <0.001 | |
| %(Cl95%) | 20 (11; 30) | 10 (4; 15) | p= 0.001 | |
| Bm3+Bm4 IgD-CD38++ |
0.69 (0.34; 1.16) | 0.54 (0.31; 0.94) | p=0.200 | |
| %(Cl95%) | 1 (1; 2) | 1 (1; 2) | p = 0.768 | |
| eBm5 IgD-CD38+ |
7.31 (5.13; 10.68) | 11.56 (8.82; 15.27) | p=0.001 | |
| %(Cl95%) | 15 (9; 24) | 25 (15; 35) | p=0.004 | |
| Bm5 IgD-CD38- |
9.42 (4,47; 13,81) | 8.62 (6.41;13.74) | p=0.363 | |
| %(Cl95%) | 17 (8; 28) | 21 (11; 35) | p=0.104 |